177 related articles for article (PubMed ID: 18789788)
1. [Pharmacogenetics and treatment response in schizophrenia].
Moulier V; Januel D
Encephale; 2007 Dec; 33(6):954-64. PubMed ID: 18789788
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine.
Zhao AL; Zhao JP; Zhang YH; Xue ZM; Chen JD; Chen XG
Int J Neurosci; 2005 Nov; 115(11):1539-47. PubMed ID: 16223700
[TBL] [Abstract][Full Text] [Related]
3. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
[TBL] [Abstract][Full Text] [Related]
4. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.
Al Hadithy AF; Ivanova SA; Pechlivanoglou P; Semke A; Fedorenko O; Kornetova E; Ryadovaya L; Brouwers JR; Wilffert B; Bruggeman R; Loonen AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):475-81. PubMed ID: 19439249
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
Scharfetter J
Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.
Shiroma PR; Geda YE; Mrazek DA
Pharmacogenomics; 2010 Sep; 11(9):1305-30. PubMed ID: 20860469
[TBL] [Abstract][Full Text] [Related]
8. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
[TBL] [Abstract][Full Text] [Related]
9. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
Auxéméry Y
Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
[TBL] [Abstract][Full Text] [Related]
10. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.
Popp J; Leucht S; Heres S; Steimer W
Pharmacogenomics J; 2009 Feb; 9(1):71-7. PubMed ID: 18332898
[TBL] [Abstract][Full Text] [Related]
11. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
[TBL] [Abstract][Full Text] [Related]
13. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Kim B; Choi EY; Kim CY; Song K; Joo YH
Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
[TBL] [Abstract][Full Text] [Related]
14. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
Kondo T; Mihara K; Suzuki A; Yasui-Furukori N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):921-6. PubMed ID: 14499308
[TBL] [Abstract][Full Text] [Related]
15. [Family based association study of DRD1, DRD2, DRD3, DRD4, DAT, COMT gene polymorphism in schizophrenia].
Paweł K; Hauser J; Skibińska M; Szczepankiewicz A; Dmitrzak-Weglarz M; Gorzkowska K; Pawlak J; Czerski PM
Psychiatr Pol; 2010; 44(3):405-13. PubMed ID: 20672519
[TBL] [Abstract][Full Text] [Related]
16. Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia.
Sáiz PA; García-Portilla MP; Arango C; Morales B; Alvarez V; Coto E; Fernández JM; Bascarán MT; Bousoño M; Bobes J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):741-5. PubMed ID: 17291660
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia.
Ohara K; Nakamura Y; Xie DW; Ishigaki T; Deng ZL; Tani K; Zhang HY; Kondo N; Liu JC; Miyasato K; Ohara K
Biol Psychiatry; 1996 Dec; 40(12):1209-17. PubMed ID: 8959285
[TBL] [Abstract][Full Text] [Related]
18. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Lane HY; Lee CC; Liu YC; Chang WH
Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients.
Shaikh S; Collier DA; Sham P; Pilowsky L; Sharma T; Lin LK; Crocq MA; Gill M; Kerwin R
Am J Med Genet; 1995 Dec; 60(6):541-5. PubMed ID: 8825892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
